INS and cancer: Sufficient data from studies on cancer cell lines and animal models suggest that metformin lowers the risk of biochemical recurrence and the rates of mortality in PCa, through its intrinsic proprieties and its pleiotropic effects linked with metformin-mediated fall in plasma glucose and insulin concentrations.